Ekso Bionics (NASDAQ:EKSO) Price Target Raised to $10.00 at HC Wainwright

Ekso Bionics (NASDAQ:EKSO) had its price target hoisted by HC Wainwright from $9.25 to $10.00 in a research report released on Tuesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Ekso Bionics’ Q2 2024 earnings at ($0.11) EPS, Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.06) EPS, FY2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.19) EPS.

Separately, StockNews.com raised Ekso Bionics from a sell rating to a hold rating in a report on Thursday, April 4th.

Ekso Bionics Trading Up 1.6 %

NASDAQ EKSO opened at $1.31 on Tuesday. The company has a quick ratio of 1.87, a current ratio of 2.81 and a debt-to-equity ratio of 0.33. Ekso Bionics has a twelve month low of $0.62 and a twelve month high of $3.13. The company has a market cap of $23.80 million, a price-to-earnings ratio of -1.35 and a beta of 1.63. The business’s fifty day moving average is $1.44 and its 200 day moving average is $1.63.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings data on Monday, April 29th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.04). Ekso Bionics had a negative net margin of 79.48% and a negative return on equity of 95.36%. The firm had revenue of $3.76 million for the quarter, compared to analyst estimates of $4.99 million. During the same period last year, the business earned ($0.33) EPS. As a group, sell-side analysts expect that Ekso Bionics will post -0.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Ekso Bionics stock. Strategic Wealth Investment Group LLC boosted its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 25.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,665 shares of the company’s stock after buying an additional 8,752 shares during the quarter. Strategic Wealth Investment Group LLC owned approximately 0.30% of Ekso Bionics worth $31,000 as of its most recent SEC filing. Institutional investors and hedge funds own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.